Drug
Rf1v 1018
Rf1v 1018: highest development phase Phase 2, developed by Dynavax Technologies. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Dynavax Technologies
Trials
| Drug | Phase | Indication |
|---|---|---|
| rF1V-1018 NCT05506969 | Phase 2 | Plague, Pneumonic |
| rF1V-1018 NCT07207408 | Phase 2 | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis |
Latest
No recent events.
Follow Rf1v 1018 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.